The American Society for Radiation Oncology (ASTRO) recognized the recipients of its 2024 Gold Medal awards and other high-profile honors during an awards ceremony during the 66th ASTRO Annual Meeting in Washington, DC. Photos of the awardees and the ceremony are available online.
Surveys from two Baltimore medical centers shed light on what may be fueling enrollment declines
People with low- and intermediate-risk prostate cancer treated with either of two types of contemporary radiation therapy 鈥� proton beam therapy or intensity modulated radiation therapy (IMRT) 鈥� achieved equally high rates of tumor control with no differences in patient-reported quality of life, according to a first-of-its-kind phase III clinical trial comparing the two technologies. Findings of the PARTIQoL trial will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
People with limited-stage small cell lung cancer may benefit from adding immunotherapy to chemoradiation, but not if both treatments are given at the same time, new research finds.
Researchers looking to de-intensify radiation treatments for people with early-stage, HPV-associated oropharyngeal cancer to prevent long-term side effects halted a large, randomized phase II/III trial after patients in the control arm reached a record high, two-year progression-free survival rate of 98%.
An accelerated course of radiation therapy does not increase complications for patients who undergo breast reconstruction following a mastectomy, new research shows. Findings of the large, phase III RT CHARM trial (Alliance A221505) will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
Analysis of three large, phase III clinical trials finds more than 40% of brain metastases patients completely reversed cognitive losses
A radiopharmaceutical therapy that has successfully extended progression-free survival for patients with neuroendocrine tumors shows early promise for delivering similar benefits to patients with difficult-to-treat meningioma, a type of brain tumor. Findings of the nonrandomized phase II study will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
In addition to the studies featured on the press program (details here) for the 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting, the following studies were recommended by ASTRO experts and may be of interest to journalists.
The American Society for Radiation Oncology (ASTRO) today announced the recipients of its 2024 research grants and fellowships, including awards co-sponsored by the American Cancer Society (ACS), the LUNGevity Foundation, the Melanoma Research Alliance (MRA), the American Association of Physicists in Medicine (AAPM), the RTOG Foundation/NRG Oncology and AstraZeneca.
The American Society for Radiation Oncology (ASTRO) announced today the seven studies to be highlighted in the 2024 ASTRO Annual Meeting press program. Researchers will discuss their findings in news briefings held September 30 and October 1 at the Walter E. Washington Convention Center in Washington, D.C. and via live webcast.
The members of the American Society for Radiation Oncology (ASTRO) recently elected five new officers to ASTRO鈥檚 Board of Directors: Neha Vapiwala, MD, FASTRO, as President-elect; Jean Wright, MD, FASTRO, as Clinical Affairs & Quality Council Vice Chair; Andrea Ng, MD, MPH, FASTRO, as Education Council Vice Chair; Christopher Corso, MD, PhD, as Government Relations Council Vice Chair; and Malika Siker, MD, FASTRO, as Health Equity, Diversity and Inclusion (HEDI) Council Vice Chair.聽The officers will begin their terms October 1 at ASTRO鈥檚 66th Annual Meeting in Washington, DC.聽
The American Society for Radiation Oncology (ASTRO) issued the following statement from Jeff M. Michalski, MD, MBA, FASTRO, Chair of the ASTRO Board of Directors, in response to the proposed 2025 Medicare Physician Fee Schedule (MPFS) released yesterday by the Centers for Medicare and Medicaid Services (CMS): 鈥淭he declines in reimbursement for radiation therapy services for people with cancer under the Medicare physician fee schedule are disappointing.
The American Society for Radiation Oncology (ASTRO) selected 48 distinguished members to receive the ASTRO Fellow (FASTRO) designation for its 2024 class of Fellows. These physician leaders will be recognized at an awards ceremony in Washington, D.C. on Tuesday, October 1 during ASTRO鈥檚 66th Annual Meeting. The ASTRO Fellows program recognizes individuals who have made substantial contributions to the Society and to the field of radiation oncology through research, education, patient care and service to the field.
The American Society for Radiation Oncology (ASTRO) announced today that following a nationwide search, Vivek S. Kavadi, MD, MBA, FASTRO will become CEO of the Society effective November 1, 2024.
The American Society for Radiation Oncology (ASTRO) published today an updated clinical guideline that details best practices for using radiation therapy to treat patients who have oropharyngeal squamous cell carcinoma (OPSCC) caused by the human papillomavirus (HPV).
The American Society for Radiation Oncology (ASTRO) applauded today鈥檚 introduction of bipartisan federal legislation to address critical flaws in the prior authorization process. 鈥淭he prior authorization system in its current form is ineffective and harmful to patients, creating unnecessary delays to lifesaving cancer treatments and distress for the people who need them,鈥� said Jeff M. Michalski, MD, MBA, FASTRO, Chair of the ASTRO Board of Directors.
The American Society for Radiation Oncology (ASTRO) published an updated clinical guideline that details best practices for treating patients who have symptomatic bone metastases and ways to improve their quality of life. The guideline is available as a free access article in Practical Radiation Oncology. 鈥淩adiation therapy is a cornerstone of care for patients with symptomatic bone metastases, offering a nonsurgical option for fast pain relief and improved quality of life with minimal side effects,鈥� said Tracy Balboni, MD, MPH, chair of the guideline task force.
Registration opens today for the American Society for Radiation Oncology's (ASTRO) 66th Annual Meeting, which will be held at the Walter E. Washington Convention Center in Washington, D.C., September 29 鈥� October 2, 2024. Media registration is also available.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal 麻豆传媒 keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right